Centre National De La Recherche Scientifique

Pierre Fabre Medicament

Christophe Long

Paola Barbara Arimondo

Yoann Menon

Yves Guminski

El Bachir Kaloun

Ludovic Halby

François Sautel

Frédéric Cantagrel

Fadila Derguini

Joséphine Beck

Paola B Arimondo

The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer. 

Hemi-synthetic trilobine analogs for use as a drug

Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.

Trilobine and its natural analogs for use as a drug

The present invention relates to a compound of following formula (I): or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for treating a proliferative disease such as cancer.

ngCycloartanone derivatives with anticancer activity

Growing community of inventors

Vielmur sur Agout, France

Christophe Long